|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Opdivo
gptkb:Yervoy
|
|
gptkbp:activities
|
immune checkpoint inhibition
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:ipilimumab
chemotherapy
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase II
oncology
Phase III
Phase I
|
|
gptkbp:combatants
|
high affinity for PD-1
|
|
gptkbp:contraindication
|
hypersensitivity to nivolumab
|
|
gptkbp:defense_mechanism
|
possible
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
depends on response
|
|
gptkbp:frequency
|
every 2 to 4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nivolumab
|
|
gptkbp:indication
|
gptkb:healthcare_organization
gptkb:classical_Hodgkin_lymphoma
gptkb:head_and_neck_squamous_cell_carcinoma
|
|
gptkbp:interacts_with
|
immunosuppressants
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_available_on
|
generic
|
|
gptkbp:is_compared_to
|
gptkb:pembrolizumab
|
|
gptkbp:is_monitored_by
|
immune-related side effects
|
|
gptkbp:is_used_for
|
treatment of cancer
|
|
gptkbp:lifespan
|
approximately 25 days
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Opdivo
|
|
gptkbp:pharmacokinetics
|
T-cell activation
linear pharmacokinetics
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
high cost
|
|
gptkbp:provides_information_on
|
NCCN guidelines
|
|
gptkbp:research
|
ongoing clinical trials
|
|
gptkbp:research_areas
|
gptkb:vaccine
|
|
gptkbp:rounds
|
hepatic
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
diarrhea
rash
immune-related adverse events
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:PD-1
|